Clinical Trial Update: Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial update evaluating oblimersen with rituximab and combination chemotherapy in relapsed or refractory aggressive non-Hodgkin lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Genasense (oblimersen sodium) (oblimersen sodium)
• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED